Raymond James Starts Covidien (COV) at Outperform
More News related to COV
- Nuvo research provides WF10 licensing and development update
- Covidien Introduces First FDA-Approved Spine Sealant
- Covidien to Present at Lazard Capital Markets Conference
- Covidien Submits Label Change for Optimark(TM) Contrast Agent
- Covidien Completes Acquisition of Aspect Medical Systems Inc.
More News related to New Coverage
- Morgan Stanley Initiates Coverage on Williams Companies (WMB) with an Overweight
- Morgan Stanley Starts ONEOK (OKE) at Underweight, $40 Price Target
- Broadpoint.Amtech Initiates Coverage on Willbros Group (WG) with a Buy; Leading North American Pipeline Contractor
- Miller Tabak Initiates Coverage on Oclaro (OCLR) with a Buy
- Natixis Bleichroeder Initiates Coverage on Gen-Probe (GPRO) with a Buy
Raymond James initiates coverage on Covidien (NYSE: COV) with an Outperform rating.
Covidien, Ltd. engages in the development, manufacture, and sale of healthcare products for use in clinical and home settings worldwide.
Related Categories
New CoverageStocks Mentioned
-0.35Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
